| ORIGINAL ARTICLE |
|
| Year : 2014 | Volume
: 11
| Issue : 2 | Page : 80-83 |
|
|
Serum levels of interleukin-17 in patients with and without acute coronary syndrome: A cross-sectional study in Babol, Northern Iran
Mehrdad Saravi1, Afshin Khani2, Ghorban Maliji3, Mohammad Khalili4, Seyedeh Khadijeh Dariabory1, Zahra Sheikh4
1 Department of Cardiovascular Diseases, Babol University of Medical Sciences, Babol, Iran
2 Student Research Committee; Cellular and Molecular Biology Research Center, Babol University of Medical Sciences, Babol, Iran
3 Cellular and Molecular Biology Research Center; Department of Immunology, Babol University of Medical Sciences, Babol, Iran
4 Student Research Committee, Babol University of Medical Sciences, Babol, Iran
Correspondence Address:
Mehrdad Saravi
Ayatollah Roohani Hospital, Babol University of Medical Sciences, Ganjafruz Street, Babol
Iran
 Source of Support: The Deputy of Research of Babol University of Medical Sciences for the financial support, Conflict of Interest: None  | Check |
DOI: 10.4103/0189-7969.142086
|
|
|
Background: The role of interleukin-17 (IL-17) in patients with acute coronary syndrome (ACS) is controversial.
Objective: The aim of this study was to assess the serum level of IL-17 in patients with acute myocardial infarction (AMI) and unstable angina (UA) in Babol, Northern Iran in 2012.
Materials and Methods: A total of 60 patients with ACS (30 with AMI, 30 with UA) and 30 healthy blood donors of Babol city, Iran were recruited in this cross-sectional study. Simple sampling method was used for patient selection. The inclusion criteria were the recent (<48 h) diagnosis of AMI or UA. The exclusion criteria were: Diagnosis of AMI or UA >48 h, recent history of infection or use of antibiotics. The serum IL-17 level was measured using enzyme-linked immunosorbent assay kit (Bioscience, Texas, USA). The lowest concentration of IL-17 that the kit could detect was 0.8 pg/ml. Chi-square, and Kruskal-Wallis tests were used for the comparison of IL-17 level between participants. P < 0.05 was considered as significant.
Results: A total of 10 participants were excluded due to contaminated blood samples. Fifty (62.5%) were males and 30 (37.5%) were females. Four (13.3%) patients of AMI group and 1 (3.3%) of UA group had detectable levels of IL-17 (P = 0.353), but no one in blood donors (P = 0.114). There was also no significant association between the presence of detectable level of IL-17 and history of diabetes mellitus, hypertension, hyperlipidemia, smoking (P > 0.05).
Conclusion: Our study did not find any significant differences in the serum level of IL-17 in individuals with or without ACS and therefore did not support the theory in which IL-17 has deleterious role in atherosclerosis. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
